Hisamitsu Pharmaceutical Stock Forecast for 2023 - 2025 - 2030
Updated on 04/27/2024
Hisamitsu Pharmaceutical Stock Forecast and Price Target
Given the average yearlong price target of ¥3950.00 provided by prominent analysts over the past few months, there is a potential upside of approximately 4.53% from the last closing price in April, 2024 for Hisamitsu Pharmaceutical's stock if it is reached. This estimation is based on a high estimate of ¥3950.00 and a low estimate of ¥3950.00. Even if you are not interested in 4530 stock, it is still imperative to be aware of its competitors.
4.53% Upside
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$146.14 | Buy/Sell | $174.55 | 16.33% |
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF89.50 | Buy/Sell | CHF105.00 | 20.25% |
| SAN Stock Forecast | Sanofi | Outperform |
16
|
91.23€ | Buy/Sell | 102.80€ | 19.48% |
| MMM Stock Forecast | 3M | Hold |
10
|
$91.83 | Buy/Sell | $109.39 | 8.90% |
| RKT Stock Forecast | Reckitt Benckiser Group | Outperform |
12
|
£44.23 | Buy/Sell | £66.68 | 22.09% |
Hisamitsu Pharmaceutical Revenue Forecast for 2023 - 2025 - 2030
In the last four years, Hisamitsu Pharmaceutical's Revenue has grown by 0.51%, rising from ¥140.99B to ¥141.71B. According to 0 analysts, Hisamitsu Pharmaceutical's Revenue will fall by 6.84% in the next year, reaching ¥132.02B. Professionals believe that By 2030, Hisamitsu Pharmaceutical's Revenue will fall to ¥131.21B – a 7.41% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAYN Stock Forecast | Bayer | Hold |
5
|
27.40€ | Buy/Sell | 45.15€ | 9.49% |
| VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$11.57 | Buy/Sell | $11.73 | 3.72% |
| H02 Stock Forecast | Haw Par Corporation | - |
16
|
$9.82 | Buy/Sell | $17.00 | -100.00% |
.jpg)
Hisamitsu Pharmaceutical Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Hisamitsu Pharmaceutical's Dividend per Share has grown, moving from ¥83.00 to ¥84.00 – an increase of 1.20%. In the following year, 0 experts forecast that Hisamitsu Pharmaceutical's Dividend per Share will decrease by 0.40%, to ¥83.66. In 2030, professionals predict that Hisamitsu Pharmaceutical's Dividend per Share will decrease by 0.33%, to ¥83.73.
Hisamitsu Pharmaceutical EBITDA Forecast for 2023 - 2025 - 2030
In the last four years, Hisamitsu Pharmaceutical's EBITDA has decreased from ¥26.98B to ¥18.34B – a 32.02% drop. For the following year, the 0 analysts predict that Hisamitsu Pharmaceutical's EBITDA will drop by 6.41%, reaching ¥17.16B. In 2030, the professionals' prediction is that 4530's EBITDA will decrease by 9.08%, reaching ¥16.67B.
Hisamitsu Pharmaceutical EBIT Forecast for 2023 - 2025 - 2030
Hisamitsu Pharmaceutical's EBIT has decreased by 42.07% In the last four years, from ¥22.73B to ¥13.17B. In the following year, the 0 analysts surveyed believe that Hisamitsu Pharmaceutical's EBIT will decrease by 5.71%, reaching ¥12.42B. According to professionals, by 2030, Hisamitsu Pharmaceutical's EBIT will have decreased by 9.59%, falling down to ¥11.91B.
Site Navigation
.jpg)